RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Melissa Johnson, MD
Tennessee Oncology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rambam Care Campus
Haifa, Israel
- Hadassah Medical Center
Jerusalem, Israel
- Shaare Zedek Medical Center
Jerusalem, Israel
- Hospital Clinico Universitario de Santiago de Compostela
A Coruña, Spain
- Next Oncology Barcelona
Barcelona, Spain
- Vall D'Hebron Insitute of Oncology
Barcelona, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Hospital Regional Universitario de Malaga
Málaga, Spain
- Hospital Quiron Madrid
Pozuelo de Alarcón, Spain
- Hospital Universitario Virgen Macarena
Seville, Spain
- Incliva Biomedical Research Institute
Valencia, Spain
- Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
- Imperial College London
London, United Kingdom
- Sarah Cannon Research Institute Uk (university College London Hospitals)
London, United Kingdom
- the Christie Nhs Foundation Trust
Manchester, United Kingdom
- Helen F. Graham Cancer Center (christiana Care)
Newark, Delaware, United States
- Cancer Treatment Centers of America
Newnan, Georgia, United States
- Hematology and Oncology Clinic
Baton Rouge, Louisiana, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Mar 2022
- Primary completion
- 30 Nov 2023
- Completion
- 31 Dec 2023
- Last update posted
- 3 Jul 2023
- Registered enrollment
- 50
- Registry id
- NCT05127590
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.